Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Apr;38(4):872–875. doi: 10.1128/aac.38.4.872

Clinical and bacteriological efficacy and tolerability of FCE 22891 in patients with exacerbations of chronic obstructive pulmonary disease.

W G Boersma 1, S M Puister 1, R van Altena 1, H G de Vries-Hospers 1, M Molinari 1, G H Koëter 1
PMCID: PMC284559  PMID: 8031062

Abstract

A beta-lactamase-stable antibiotic, the oral penem FCE 22891 (ritipenem acoxil), was investigated for use in exacerbations of chronic obstructive pulmonary disease (COPD). Thirteen of the 15 COPD patients had a proven lower respiratory tract infection. Symptom scores and forced expiratory volumes in 1 s significantly improved during therapy with FCE 22891 in combination with bronchodilators and intravenous corticosteroids. Conversion of representative sputum to nonrepresentative sputum or eradication of the original pathogen in representative sputum was effected in 12 patients. Resistance to FCE 22891 was observed in three cases with Haemophilus influenzae. Gastrointestinal disturbances, of which one was severe, were experienced by eight patients. Although FCE 22891 has some beneficial effect in exacerbations of COPD, there are reservations about its use because of adverse effects and potential inefficacy in the treatment of infection with H. influenzae.

Full text

PDF
872

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Jones R. N., Thornsberry C. In-vitro activity of the penem, FCE 22101, and tentative interpretive criteria for disc susceptibility tests. J Antimicrob Chemother. 1989 Mar;23 (Suppl 100):17–30. doi: 10.1093/jac/23.suppl_c.17. [DOI] [PubMed] [Google Scholar]
  2. Burrows B., Earle R. H. Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. N Engl J Med. 1969 Feb 20;280(8):397–404. doi: 10.1056/NEJM196902202800801. [DOI] [PubMed] [Google Scholar]
  3. Dornbusch K., Kronvall G., Göransson E., Mörtsell E. In-vitro activity of FCE 22101 against respiratory tract pathogens with reference to production of beta-lactamases. J Antimicrob Chemother. 1989 Mar;23 (Suppl 100):31–41. doi: 10.1093/jac/23.suppl_c.31. [DOI] [PubMed] [Google Scholar]
  4. Franceschi G., Foglio M., Alpegiani M., Battistini C., Bedeschi A., Perrone E., Zarini F., Arcamone F., Della Bruna C., Sanfilippo A. Synthesis and biological properties of sodium (5R, 6S, 8R)-6 alpha-hydroxyethyl-2-carbamoyloxymethyl-2-penem-3-carboxylate (FCE 22101) and its orally absorbed esters FCE 22553 and FCE 22891. J Antibiot (Tokyo) 1983 Jul;36(7):938–941. doi: 10.7164/antibiotics.36.938. [DOI] [PubMed] [Google Scholar]
  5. Hager H., Verghese A., Alvarez S., Berk S. L. Branhamella catarrhalis respiratory infections. Rev Infect Dis. 1987 Nov-Dec;9(6):1140–1149. doi: 10.1093/clinids/9.6.1140. [DOI] [PubMed] [Google Scholar]
  6. Hoban D. J. In-vitro activity of a new penem FCE 22101. J Antimicrob Chemother. 1989 Mar;23 (Suppl 100):53–57. doi: 10.1093/jac/23.suppl_c.53. [DOI] [PubMed] [Google Scholar]
  7. Jorgensen J. H., Doern G. V., Maher L. A., Howell A. W., Redding J. S. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 1990 Nov;34(11):2075–2080. doi: 10.1128/aac.34.11.2075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kayser F. H., Morenzoni G., Santanam P. The Second European Collaborative Study on the frequency of antimicrobial resistance in Haemophilus influenzae. Eur J Clin Microbiol Infect Dis. 1990 Nov;9(11):810–817. doi: 10.1007/BF01967379. [DOI] [PubMed] [Google Scholar]
  9. MULDER J. CLINICAL SIGNIFICANCE OF BACTERIOLOGIC EXAMINATION OF SPUTUM IN CASES OF ACUTE AND CHRONIC BACTERIAL DISEASE OF RESPIRATORY TRACT. Adv Intern Med. 1964;12:233–255. [PubMed] [Google Scholar]
  10. Machka K., Braveny I., Dabernat H., Dornbusch K., Van Dyck E., Kayser F. H., Van Klingeren B., Mittermayer H., Perea E., Powell M. Distribution and resistance patterns of Haemophilus influenzae: a European cooperative study. Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):14–24. doi: 10.1007/BF01962165. [DOI] [PubMed] [Google Scholar]
  11. Murphy T. F., Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1992 Oct;146(4):1067–1083. doi: 10.1164/ajrccm/146.4.1067. [DOI] [PubMed] [Google Scholar]
  12. Neu H. C., Chin N. X., Labthavikul P. The in-vitro activity of a novel penem FCE 22101 compared to other beta-lactam antibiotics. J Antimicrob Chemother. 1985 Sep;16(3):305–313. doi: 10.1093/jac/16.3.305. [DOI] [PubMed] [Google Scholar]
  13. Nord C. E., Lindmark A., Person I. Susceptibility of anaerobic bacteria to FCE 22101. Antimicrob Agents Chemother. 1987 May;31(5):831–833. doi: 10.1128/aac.31.5.831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Saathoff A., Lode H., Hampel B., Deppermann K. M., Borner K., Koeppe P. Pharmacokinetics of FCE 22891, a new oral penem. Antimicrob Agents Chemother. 1990 Jun;34(6):1001–1006. doi: 10.1128/aac.34.6.1001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Standardized lung function testing. Report working party. Bull Eur Physiopathol Respir. 1983 Jul;19 (Suppl 5):1–95. [PubMed] [Google Scholar]
  16. Wallace R. J., Jr, Nash D. R., Steingrube V. A. Antibiotic susceptibilities and drug resistance in Moraxella (Branhamella) catarrhalis. Am J Med. 1990 May 14;88(5A):46S–50S. doi: 10.1016/0002-9343(90)90262-c. [DOI] [PubMed] [Google Scholar]
  17. Webberley J. M., Wise R., Andrews J. M., Ashby J. P., Wallbridge D. The pharmacokinetics and tissue penetration of FCE 22101 following intravenous and oral administration. J Antimicrob Chemother. 1988 Apr;21(4):445–450. doi: 10.1093/jac/21.4.445. [DOI] [PubMed] [Google Scholar]
  18. Wise R., Andrews J. M., Danks G. Comparison of in vitro activity of FCE 22101, a new penem, with those of other beta-lactam antibiotics. Antimicrob Agents Chemother. 1983 Dec;24(6):909–914. doi: 10.1128/aac.24.6.909. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES